KPRX

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. (KPRX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.6
EV / EBITDA 0.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -47.8%
Price Return 12M -41.9%
Catalyst Signal 0.00
Market Cap $5.9M
TTM Revenue N/A
Price / Sales N/A
ROE -56.4%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.7) D+ (1.8) C+ (2.8) C (2.2) C+ (2.6) C+ (2.6)
2026-11-06 B+ (3.8) D+ (1.8) C+ (2.8) C (2.3) C+ (2.7) C+ (2.7)
2026-10-30 B+ (3.7) D+ (1.8) C+ (2.8) C (2.5) C+ (2.7) C+ (2.7)
2026-10-23 B+ (3.7) C- (1.9) B- (2.9) C+ (2.7) C+ (2.6) C+ (2.7)
2026-10-16 B+ (3.7) D+ (1.8) B- (2.9) C+ (2.6) C+ (2.6) C+ (2.7)
Page 1 of 4